HOUSTON, June 1, 2026
Iterion Therapeutics has unveiled compelling clinical data supporting tegavivint, its first-in-class Wnt/β-catenin pathway inhibitor, as a targeted therapy for patients with Wnt-driven advanced hepatocellular carcinoma (HCC). Presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the findings mark the first clinical validation of tegavivint’s mechanism of action in a genetically defined population of liver cancer patients. The study demonstrated meaningful anti-tumor activity, durable disease control, and clear biological evidence of Wnt pathway inhibition in patients whose tumors carried Wnt pathway-activating mutations (WPAMs). With approximately 40% of advanced HCC patients harboring Wnt-driven tumors and no approved targeted therapies currently available for this molecular subgroup, the results position tegavivint as a potentially transformative precision oncology treatment for a significant unmet medical need. The findings also reinforce the growing importance of biomarker-driven therapeutic strategies in the treatment of advanced cancers.
Strong Clinical Responses Demonstrated in Wnt-Driven Liver Cancer
The ongoing Phase 1/2 clinical study enrolled 40 patients with advanced hepatocellular carcinoma, most of whom had previously received multiple lines of systemic therapy. Of the enrolled patients, 73% carried Wnt pathway-activating mutations, including alterations in AXIN1, CTNNB1, CREBBP, and APC genes identified through circulating tumor DNA testing. Among efficacy-evaluable patients treated within the recommended dose range, tegavivint demonstrated encouraging clinical activity almost exclusively in patients with Wnt-driven disease. Approximately 40% of patients experienced measurable tumor shrinkage, while the therapy achieved a 72% disease control rate across evaluable patients with WPAM-positive tumors. Particularly noteworthy were outcomes among second- and third-line patients, where tegavivint delivered a 22% overall response rate, an impressive 89% disease control rate, and a median progression-free survival of eight months. No tumor shrinkage was observed in patients lacking Wnt pathway mutations, further validating the drug’s precision-targeted approach and supporting the importance of molecular patient selection.
First Clinical Proof of Wnt/β-Catenin Pathway Inhibition
A key objective of the study was to determine whether tegavivint could successfully inhibit the Wnt/β-catenin signaling pathway, a major driver of tumor growth, survival, and treatment resistance in several cancers. Researchers reported compelling biomarker evidence confirming the therapy’s mechanism of action. Paired tumor analyses revealed significant reductions in active β-catenin protein levels following treatment, while additional assessments showed dose-dependent decreases in alpha-fetoprotein (AFP) and reductions in Wnt mutation-associated circulating tumor DNA.
Advertisement
These findings provide direct clinical confirmation that tegavivint is successfully targeting the biological pathway it was designed to inhibit. The results are particularly important because Wnt/β-catenin signaling has long been recognized as a challenging therapeutic target despite its central role in numerous malignancies. By demonstrating both pathway inhibition and corresponding clinical benefit, the study establishes a strong foundation for future development of tegavivint across multiple Wnt-driven tumor types.
Favorable Safety Profile Supports Continued Development
In addition to demonstrating promising efficacy, tegavivint exhibited a generally favorable safety and tolerability profile. Treatment-related adverse events occurred in 68% of patients but were predominantly Grade 1 or Grade 2, with fatigue, anemia, decreased appetite, hyperbilirubinemia, and muscle pain among the most commonly reported events. A reversible Grade 3 anemia event observed at the highest dose level helped establish a recommended therapeutic dose range of 3 to 6.5 mg/kg. Investigators reported that the therapy was overall well tolerated, supporting continued advancement into later-stage clinical development.
Beyond advanced HCC, tegavivint is also being evaluated in additional Wnt-driven cancers, including metastatic colorectal cancer and pediatric osteosarcoma. As precision oncology continues to evolve, the ability to match highly selective therapies with genetically defined patient populations is increasingly viewed as a cornerstone of future cancer care. The positive ASCO 2026 findings strengthen Iterion Therapeutics’ position as a leader in Wnt-targeted oncology and highlight tegavivint’s potential to become the first targeted treatment specifically developed for patients with Wnt-driven hepatocellular carcinoma.
Source: Iterion Therapeutics press release
